Hereditary ovarian cancer: Molecular genetics and clinical implications

Gynecologic Oncology

Volumn 64, Issue 2, 1997, Pages 196-206

  Boyd, Jeff ^a   Rubin, Stephen C ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER; CANCER SUSCEPTIBILITY; FAMILIAL CANCER; FEMALE; GENE MUTATION; GENETIC LINKAGE; GENETIC SCREENING; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MOLECULAR GENETICS; OVARIECTOMY; OVARY CANCER; PRIORITY JOURNAL; REVIEW; TREATMENT PLANNING;

EID: 0031081108     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1996.4572     Document Type: Review

References (152)

1. 1. Cancer Facts and Figures - 1996, Atlanta, American Cancer Society, 1996
2. 2. Ozols RF, et al.: Epithelial ovarian cancer, in Hoskins WJ, Perez CA, Young RC (eds): Principles and Practice of Gynecologic Oncology, Philadelphia, JB Lippincott, 1992, pp 731-781
3. 3. Casagrande JT, et al: "Incessant ovulation" and ovarian cancer. Lancet 2:170-172, 1979
4. 4. Parazzini F, et al: The epidemiology of ovarian cancer. Gynecol Oncol 43:9-23, 1991
5. 5. Bishop JM: Molecular themes in oncogenesis. Cell 64:235-248, 1991
6. 6. Weinberg RA: Oncogenes, antioncogenes, and the molecular basis of multistep carcinogenesis. Cancer Res 49:3713-3721, 1989
7. 7. Boyd J, Barrett JC: Genetic and cellular basis of multistep carcinogenesis. Pharmacol Ther 46:469-486, 1990
8. 8. Renan MJ: How many mutations are required for tumorigenesis? Implications from human cancer data. Mol Carcinog 7:139-146, 1993
9. 9. Mok SC, et al: Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy. Cancer Res 53:1489-1492, 1993
10. 10. Teneriello MG, et al: p53 and Ki-ras gene mutations in epithelial ovarian neoplasms. Cancer Res 53:3103-3108, 1993
11. 11. Ichikawa Y, et al.: Mutation of K-ras protooncogene is associated with histological subtypes in human mucinous ovarian tumors. Cancer Res 54:33-35, 1994
12. 12. Slamon DJ, et al.: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712, 1989
13. 13. Berchuck A, et al: Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 50:4087-4091, 1990
14. 14. Rubin SC, et al.: Prognostic significance of HER-2/neu expression in advanced epithelial ovarian cancer: A multivariate analysis. Am J Obstet Gynecol 168:162-169, 1993
15. 15. Felip E, et al.: Overexpression of c-erbB-2 in epithelial ovarian cancer: Prognostic value and relationship with response to therapy. Cancer 75:2147-2152, 1995
16. 16. Berchuck A, et al: The p53 tumor suppressor gene frequently is altered in gynecologic cancers. Am J Obstet Gynecol 170:246-252, 1994
17. 17. Henriksen R, et al.: p53 expression in epithelial ovarian neoplasms: Relationship to clinical and pathological parameters, Ki-67 expression and flow cytometry. Gynecol Oncol 53:301-306, 1994
18. 18. Levesque MA, et al: Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer 75:1327-1338, 1995
19. 19. Lee JH, et al: Frequent loss of heterozygosity on chromosomes 6q, 11, and 17 in human ovarian carcinomas. Cancer Res 50:2724-2728, 1990
20. 20. Sato T, et al: Allelotype of human ovarian cancer. Cancer Res 51:5118-5122, 1991
21. 21. Gallion HH, et al: Molecular genetic changes in human epithelial ovarian malignancies. Gynecol Oncol 47:137-142, 1992
22. 22. Cliby W, et al: Human epithelial ovarian cancer allelotype. Cancer Res 53:2393-2398, 1993
23. 23. Yang-Feng TL, et al.: Allelic loss in ovarian cancer. Int. J. Cancer 54:546-551, 1993
24. 24. Weitzel JN, et al. : Molecular genetic changes associated with ovarian cancer. Gynecol Oncol 55:245-252, 1994
25. 25. Schildkraut JM, Thompson WD: Familial ovarian cancer: A population-based case - control study. Am J Epidemiol 128:456-466, 1988
26. 26. Amos CI, et al: Age at onset for familial epithelial ovarian cancer. JAMA 268:1896-1899, 1992
27. 27. Amos, CI, Struewing JP: Genetic epidemiology of epithelial ovarian cancer. Cancer 71:566-572, 1993
28. 28. Greggi S, et al: Analysis of 138 consecutive ovarian cancer patients: Incidence and characteristics of familial cases. Gynecol Oncol 39:300-304, 1990
29. 29. Houlston RS, et al: Genetic epidemiology of ovarian cancer: Segregation analysis. Ann Hum Genet 55:291-299, 1991
30. 30. Narod SA, et al.: Hereditary and familial ovarian cancer in southern Ontario. Cancer 74:2341-2346, 1994
31. 31. Go RCP, et al.: Genetic epidemiology of breast cancer and associated cancers in high risk families. I. Segregation analysis. J Natl Cancer Inst 71:455-461, 1983
32. 32. Piver MS, et al.: Familial ovarian cancer: A report of 658 families from the Gilda Radner Familial Ovarian Cancer Registry 1981-1991. Cancer 71:582-588, 1993
33. 33. Lynch HT, et al.: Hereditary ovarian cancer: Heterogeneity at age of diagnosis. Cancer 67:1460-1466, 1991
34. 34. Bewtra C, et al.: Hereditary ovarian cancer: A clinicopathological study. Int J Gynecol Pathol 11:180-187, 1992
35. 35. Schildkraut JM, Risch N, Thompson WD: Evaluating genetic association among ovarian, breast, and endometrial cancer: Evidence for a breast/ovarian cancer relationship. Am J Hum Genet 45:521-529, 1989
36. 36. Lynch HT, Conway T, Lynch J: Hereditary ovarian cancer: Pedigree studies, part II. Cancer Genet Cytogenet 52:161-183, 1991
37. 37. Watson P, Lynch HT: Extracolonic cancer in hereditary nonpolyposis colorectal cancer. Cancer 71:677-685, 1993
38. 38. Steichen-Gersdorf E, et al.: Familial site-specific ovarian cancer is linked to BRCA1 on 17q12-21. Am J Hum Genet 55:870-875, 1994
39. 39. Lynch HT, et al.: Familial association of breast/ovarian carcinoma. Cancer 41:1543-1548, 1978
40. 40. Easton DF, et al: Genetic linkage analysis in familial breast and ovarian cancer: Results from 214 families. The Breast Cancer Linkage Consortium. Am J Hum Genet 52:678-701, 1993
41. 41. Narod SA, et al: An evaluation of genetic heterogeneity in 145 breast - ovarian cancer families. Am J Hum Genet 56:254-264, 1995
42. 42. Hall JM, et al: Linkage of early-onset familial breast cancer to chromosome 17q21. Science 250:1684-1689, 1990
43. 43. Narod SA, et al.: Familial breast - ovarian cancer locus on chromosome 17q12-q23. Lancet 338:82-83, 1991
44. 44. Wooster R, et al: Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 265:2088-2090, 1994
45. 45. Narod S, et al: Genetic heterogeneity of breast - ovarian cancer revisited. Am J Hum Genet 57:957-958, 1995
46. 46. Lynch HT, et al: Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer. Gastroenterology 104:1535-1549, 1993
47. 47. Peltomäki P, et al: Genetic mapping of a locus predisposing to human colorectal cancer. Science 260:810-812, 1993
48. 48. Lindblom A, et al: Genetic mapping of a second locus predisposing to hereditary nonpolyposis colon cancer. Nature Genet 5:279-282, 1993
49. 49. Nystrom-Lahti M, et al.: Mismatch repair genes on chromosomes 2p and 3p account for a major share of hereditary nonpolyposis colorectal cancer families evaluable by linkage. Am J Hum Genet 55:659-665, 1994
50. 50. Nicolaides NC, et al.: Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. Nature 371:75-80, 1994
51. 51. Narod S, et al.: Histology of BRCA1-associated ovarian tumours. Lancet 343:236, 1994
52. 52. Rubin SC, et al: Clinicopathologic characteristics of ovarian cancers occurring in women with germline mutations of BRCA1. N Engl J Med 335:1413-1416, 1996
53. 53. Sutherland GR, Richards RI: Anticipation legetimized: Unstable DNA to the rescue. Am J Hum Genet 51:7-9, 1992
54. 54. Friedman LS, et al.: Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families. Nature Genet 8:399-404, 1994
55. 55. Struewing JP, et al: Detection of eight BRCA1 mutations in 10 breast/ ovarian cancer families, including one family with male breast cancer. Am J Hum Genet 57:1-7, 1995
56. 56. Muto MG, et al.: Frequency of the BRCA1 185delAG mutation among Jewish women with ovarian cancer and matched population controls. Cancer Res 56:1250-1252, 1996
57. 57. Johannsson O, et al.: Founding BRCA1 mutations in hereditary breast and ovarian cancer in southern Sweden. Am J Hum Genet 58:441-450, 1996
58. 58. Buller RE, et al.: Familial ovarian cancer. Gynecol Oncol 51:160-166, 1993
59. 59. Porter DE, et al.: Breast cancer incidence, penetrance and survival in probable carriers of BRCA1 gene mutation in families linked to BRCA1 on chromosome 17q12-21. Br J Surg 81:1512-1515, 1994
60. 60. Miki Y, et al.: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66-71, 1994
61. 61. Castilla LH, et al.: Mutations in the BRCA1 gene in families with early-onset breast and ovarian cancer. Nature Genet 8:387-391, 1994
62. 62. Simard J, et al. : Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families. Nature Genet 8:392-398, 1994
63. 63. Futreal PA, et al: BRCA1 mutations in primary breast and ovarian cancers. Science 266:120-122, 1994
64. 64. Shattuck-Eidens D, et al.: A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. JAMA 273:535-541, 1995
65. 65. Takahashi H, et al: Mutation analysis of the BRCA1 gene in ovarian cancers. Cancer Res 55:2998-3002, 1995
66. 66. Marquis ST, et al: The developmental pattern of BRCA1 expression implies a role in differentiation of breast and other tissues. Nature Genet 11:17-26, 1995
67. 67. Jensen RA, et al.: BRCA1 is secreted and exhibits properties of a granin. Nature Genet 12:303-308, 1996
68. 68. Chen Y, et al: Aberrant subcellular localization of BRCA1 in breast cancer. Science 270:789-791, 1995
69. 69. Scully R, et al.: Location of BRCA1 in human breast and ovarian cancer cells. Science 272:123-126, 1996
70. 70. Holt JT, et al.: Growth retardation and tumour inhibition by BRCA1. Nature Genet 12:298-302, 1996
71. 71. Smith SA, et al.: Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome. Nature Genet 2:128-131, 1992
72. 72. Merajver SD, et al.: Germline BRCA1 mutations and loss of the wild-type allele in tumors from families with early-onset breast and ovarian cancer. Clin Cancer Res 1:539-544, 1995
73. 73. Gayther SA, et al.: Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype - phenotype correlation. Nature Genet 11:428-433, 1995
74. 74. Phelan CM, et al.: Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus. Nature Genet 12:309-311, 1996
75. 75. Russell SEH, et al. : Allele loss from chromosome 17 in ovarian cancer. Oncogene 5:1581-1583, 1990
76. 76. Foulkes W, et al.: Allele loss on chromosome 17q in sporadic ovarian cancer. Lancet 338:444-445, 1991
77. 77. Eccles DM, et al.: Early loss of heterozygosity on 17q in ovarian cancer. Oncogene 7:2069-2072, 1992
78. 78. Merajver SD, et al.: Somatic mutations in the BRCA1 gene in sporadic ovarian tumours. Nature Genet 9:439-443, 1995
79. 79. Hosking L, et al: A somatic BRCA1 mutation in an ovarian tumor. Nature Genet 9:343-344, 1995
80. 80. Matsushima M, et al: Mutation analysis of the BRCA1 gene in 76 Japanese ovarian cancer patients: Four germline mutations, but no evidence of somatic mutation. Hum Mol Genet 4:1953-1956, 1995
81. 81. Jacobs IJ, et al: A deletion unit on chromosome 17q in epithelial ovarian tumors distal to the familial breast/ovarian cancer locus. Cancer Res 53:1218-1221, 1993
82. 82. Saito H, et al.: Detailed deletion mapping of chromosome 17q in ovarian and breast cancers: 2-cM region on 17q21.3 often and commonly deleted in tumors. Cancer Res 53:3382-3385, 1993
83. 83. Godwin AK, et al.: A common region of deletion on chromosome 17q in both sporadic and familial epithelial ovarian tumors distal to BRCA1. Am J Hum Genet 55:666-677, 1994
84. 84. Wooster R, et al.: Identification of the breast cancer susceptibility gene BRCA2. Nature 378:789-792, 1995
85. 85. Tavtigian SV, et al.: The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nature Genet 12:333-337, 1996
86. 86. Thorlacius S, et al.: A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nature Genet 13:117-119, 1996
87. 87. Phelan CM, et al.: Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families. Nature Genet 13:120-122, 1996
88. 88. Couch FJ, et al: BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nature Genet 13:123-125, 1996
89. 89. Gudmundsson J, et al: Frequent occurrence of BRCA2 linkage in Icelandic breast cancer families and segregation of a common BRCA2 haplotype. Am J Hum Genet 58:749-756, 1996
90. 90. Takahashi H, et al.: Mutations of the BRCA2 gene in ovarian carcinomas. Cancer Res 56:2738-2341, 1996
91. 91. Collins N, et al: Consistent loss of the wild-type allele in breast cancers from a family linked to the BRCA2 gene on chromosome 13q12-13. Oncogene 10:1673-1675, 1995
92. 92. Gudmundsson J, et al.: Different tumor types from BRCA2 mutation carriers show wild-type chromosome deletions on 13q12-q13. Cancer Res 55:4830-4832, 1995
93. 93. Fishel R, et al.: Binding of mismatched microsatellite DNA sequences by the human MSH2 protein. Science 266:1403-1405, 1994
94. 94. Leach FS, et al.: Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell 75:1215-1225, 1993
95. 95. Bronner CE, et al.: Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature 368:258-261, 1994
96. 96. Papadopoulos N, et al: Mutation of a mutL homolog in hereditary colon cancer. Science 263:1625-1629, 1994
97. 97. Aaltonen LA, et al.: Clues to the pathogenesis of familial colorectal cancer. Science 260:812-816, 1993
98. 98. Risinger JI, et al: Genetic instability of microsatellites in endometrial carcinoma. Cancer Res 53:5100-5103, 1993
99. 99. Aaltonen LA, et al.: Replication errors in benign and malignant tumors from hereditary nonpolyposis colorectal cancer patients. Cancer Res 54:1645-1648, 1994
100. + tumor cells. Cell 75:1227-1236, 1993
101. 101. Umar A, et al: Defective mismatch repair in extracts of colorectal and endometrial cancer cell lines exhibiting microsatellite instability. J Biol Chem 269:14367-14370, 1994
102. 102. Risinger JI, et al.: A hPMS2 mutant cell line is defective in strand-specific mismatch repair. J Biol Chem 270:18183-18186, 1995
103. 103. Risinger JI, et al.: Microsatellite instability in gynecological sarcomas and in hMSH2 mutant uterine sarcoma cell lines defective in mismatch repair activity. Cancer Res 55:5664-5669, 1995
104. 104. Li G-M, Modrich P: Restoration of mismatch repair to nuclear extracts of H6 colorectal tumor cells by a heterodimer of human MutL homologs. Proc Natl Acad Sci USA 92:1950-1954, 1995
105. 105. Koi M, et al.: Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N′-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation. Cancer Res 54:4308-4312, 1994
106. 106. Hemminki A, et al.: Loss of the wild-type MLH1 gene is a feature of hereditary nonpolyposis colorectal cancer. Nature Genet 8:405-410, 1994
107. 107. Liu B, et al.: Mismatch repair gene defects in sporadic colorectal cancers with microsatellite instability. Nature Genet 9:48-55, 1995
108. 108. Loeb LA: Microsatellite instability: Marker of a mutator phenotype in cancer. Cancer Res 54:5059-5063, 1994
109. 109. Modrich P: Mismatch repair, genetic stability, and cancer. Science 266:1959-1960, 1994
110. 110. Fishel R, et al.: The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 75:1027-1038, 1993
111. 111. Kolodner RD, et al.: Structure of the human MSH2 locus and analysis of two Muir - Torre kindreds for msh2 mutations. Genomics 24:516-526, 1994
112. 112. Liu B, et al.: hMSH2 mutations in hereditary nonpolyposis colorectal cancer kindreds. Cancer Res 54:4590-4594, 1994
113. 113. Kolodner RD, et al: Structure of the human MLH1 locus and analysis of a large hereditary nonpolyposis colorectal cancer kindred for mlh1 mutations. Cancer Res 55:242-248, 1995
114. 114. Wijnen J, et al.: Seven new mutations in hMSH2, an HNPCC gene, identified by denaturing gradient-gel electrophoresis. Am J Hum Genet 56:1060-1066, 1995
115. 115. Katabuchi H, et al: Mutations in DNA mismatch repair genes are not responsible for microsatellite instability in most sporadic endometrial carcinomas. Cancer Res 55:5556-5560, 1995
116. 116. Markowitz S, et al.: Inactivation of the type II TGF-β receptor in colon cancer cells with microsatellite instability. Science 268:1336-1338, 1995
117. 117. Parsons R, et al.: Microsatellite instability and mutations of the transforming growth factor β type II receptor gene in colorectal cancer. Cancer Res 55:5548-5550, 1995
118. 118. Getzenberg RH, et al: Nuclear structure and the three-dimensional organization of DNA. J Cell Biochem 47:289-299, 1991
119. 119. Boulikas T, Kong CF: Multitude of inverted repeats characterizes a class of anchorage sites of chromatin loops to the nuclear matrix. J Cell Biochem 53:1-12, 1993
120. 120. Statement of the American Society of Human Genetics on genetic testing for breast and ovarian cancer predisposition. Am J Hum Genet 55:i-iv, 1994
121. 121. Statement on use of DNA testing for presymptomatic identification of cancer risk. JAMA 271:785, 1994
122. 122. Statement of the American Society of Clinical Oncology: Genetic testing for cancer susceptibility. J Clin Oncol 14:1730-1736, 1996
123. 123. Collins FS: BRCA1-lots of mutations, lots of dilemmas. N Engl J Med 334:186-188, 1996
124. 124. Holtzman NA: Are we ready to screen for inherited susceptibility to cancer? Oncology 10:57-64, 1996
125. 125. Lynch HT, Lynch J: Genetic counseling for hereditary cancer. Oncology 10:27-34, 1996
126. 126. Menko FH, et al.: Genetic counseling in hereditary nonpolyposis colorectal cancer. Oncology 10:71-76, 1996
127. 127. Biesecker BB, et al.: Genetic counseling for families with inherited susceptibility to breast and ovarian cancer. JAMA 269:1970-1974, 1993
128. 128. Hoskins KF, et al.: Assessment and counseling for women with a family history of breast cancer. JAMA 273:577-585, 1995
129. 129. Lerman C, et al: BRCA1 testing in families with hereditary breast -ovarian cancer: A prospective study of patient decision making and outcomes. JAMA 275:1885-1892, 1996
130. 130. Botkin JR, et al.: A model protocol for evaluating the behavioral and psychosocial effects of BRCA1 testing. J Natl Cancer Inst 88:872-882, 1996
131. 131. American Society of Human Genetics Board of Directors and American College of Medical Genetics Board of Directors: Points to consider: Ethical, legal, and psychosocial implications of genetic testing in children and adolescents. Am J Hum Genet 57:1233-1241, 1995
132. 132. Ad Hoc Committee on Genetic Testing/Insurance Issues: Background statement: Genetic testing and insurance. Am J Hum Genet 56:327-331, 1995
133. 133. Eastern DF, et al.: Breast and ovarian cancer incidence in BRCA1-mutation carriers. Am J Hum Genet 56:265-271, 1995
134. 134. Ford D, Easton DF, Peto J: Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet 57:1457-1462, 1995
135. 135. Struewing JP, et al: The carrier frequency of the BRCA1 185delAG mutation is approximately 1% in Ashkenazi Jewish individuals. Nature Genet 11:198-200, 1995
136. 136. Fitzgerald MG, et al.: Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer. N Engl J Med 334:143-149, 1996
137. 137. Neuhausen S, et al.: Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer. Nature Genet 13:126-128, 1996
138. 138. Roa BB, et al.: Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nature Genet 14:185-187, 1996
139. 139. Oddoux C, et al: The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nature Genet 14:188-190, 1996
140. 140. Marra G, Boland CR: Hereditary nonpolyposis colorectal cancer: The syndrome, the genes, and historical perspectives. J Natl Cancer Inst 87:1114-1125, 1995
141. 141. Nystrom-Lahti M, et al: Founding mutations and Alu-mediated recombination in hereditary colon cancer. Nature Med 1:1203-1206, 1995
142. 142. Tobacman JK, et al: Intraabdominal carcinomatosis after prophylactic oophorectomy in ovarian cancer prone families. Lancet 2:795-797, 1982
143. 143. Lynch HT, Bewtra C, Lynch JF: Familial ovarian cancer: Clinical nuances. Am J Med 81:1073-1076, 1986
144. 144. Piver MS, et al: Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer: A report of the Gilda Radner Familial Ovarian Cancer Registry. Cancer 71:2751-2755, 1993
145. 145. Chen KTK, Schooley JF, Flam MS: Peritoneal carcinomatosis after prophylactic oophorectomy in familial ovarian cancer syndrome. Obstet Gynecol 66:93S-94S, 1985
146. 146. Menczer J, Ben-Baruch G: Familial ovarian cancer in Israeli Jewish women. Obstet Gynecol 77:276-277, 1991
147. 147. Lynch HT, Conway T, Lynch J: Hereditary ovarian cancer, in Sharp F, Mason WP, Leake RE (eds): Ovarian Cancer: Biological and Therapeutic Challenges, New York, WW Norton, 1990, pp 7-19
148. 148. Jacobs I, Oram D: Prevention of ovarian cancer: A survey of the practice of prophylactic oophorectomy by fellows and members of the Royal College of Obstetricians and Gynaecologists. Br J Obstet Gynaecol 96:510-515, 1989
149. 149. Campbell S, et al: Transabdominal ultrasound screening for early ovarian cancer. Br Med J 299:1363-1367, 1989
150. 150. Van Nagell JR, et al: Transvaginal sonography as a screening method for ovarian cancer. Cancer 65:573-577, 1990
151. 151. Zurawski VR, et al: Serum CA 125 levels in a group of nonhospitalized women: Relevance for the early detection of ovarian cancer. Obstet Gynecol 69:606-611, 1987
152. 152. Olt GJ, Berchuck A, Bast RC: Gynecologic tumor markers. Semin Surg Oncol 6:305-313, 1990